MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

| P E 40 Substitute for form 1449B/PTO | Complete if Known | | |
|--|------------------------|---------------------------|--|
| TO THE TOP TO THE TO THE TOP TO T | Application Number | 10/522,130 | |
| TO THE STATEMENT BY APPLICANT | Filing Date | 01/19/2005 | |
| 10100° B | First Named Inventor | Murray Goodman | |
| FED & | Group Art Unit | | |
| (use as many sheets as necessary) | Examiner Name | | |
| Sheetrage 1 of 2 | Attorney Docket Number | SDUC1100J-1 (041673-3109) | |

| | | | | U.S. PATENT DOCUMENTS | | |
|-----------------------|--------------|----------------------|---|--|------------------------------|--|
| Examiner Initials* | | U.S. Patent Document | | | Date of Publication of | Pages, Columns, Lines, Where Relevant |
| | Cite No.1 | Number | Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Cited Document MM-DD-YYYY | Passages or Relevant Figures Appear |
| | | | | | | |

| Examiner Initials* | Cite No.1 | Office ³ | oreign Patent D | Nocument Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Documents | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | 16 |
|-----------------------|--------------|---------------------|-----------------|--|--|--|--|----|
| | A1 | wo | 91/09958 | | Whitehead Institute for Biomedical Research | 07-11-1991 | | |
| | A2 | wo | 94/04686 | | Biogen, Inc. | 03-03-1994 | | |
| | A3 | wo | 98/52614 | | The Board of Trustees of the Leland Stanford Junior University | 11-26-1998 | | |

| | - | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|--|----|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T€ |
| | A4 | BUSCHLE, M. et al., Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA., 94, p. 3256-3261 (1997). | |
| | A5 | EMI, N. et al., Gene Transfer Mediated by Polyarginine Requires a Formation of Big Carrier-Complex of DNA Aggregate, Biophys. Res. Commun., 231, p. 421-424 (1997). | |
| | A6 | FEICHTINGER, L. et al., Triurethane-Protected Guanidines and Triflydiurethane-Protected Guanidines: New Reagents for Guanidinylation Reactions, J. Org. Chem., 63, p. 8432 (1998). | |
| | A7 | LEONETTI, JP. et al., Biological Activity of Oligonucleotide-Poly(L-lysine) Conjugates: Mechanism of Cell Uptake, Bioconjugate Chem., 1, p. 149-153 (1990). | |
| | A8 | MITCHELL, D.J. et al., Polyargine enters cells more efficiently than other polycationic homopolymers, J. Peptide Res., 55 p. 318-325 (2000). | |
| | A9 | MURPHY, J.E. et al., A combinatorial approach to the discovery of efficient cationic peptoid reagents for gene delivery, Proc. Natl. Acad. Sci. USA., 95, p. 1517-1522 (1998). | |

| Examiner | Date |
|-----------|------------|
| Signature | Considered |
| Signature | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. See attached Kinds of U.S. Patient Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patient document. ³kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark, Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MODIFIED PTO/SB/08 (08-0C
Approved for use through 10/31/2002. OMB 0651-003
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

| | Substitute for t | form 1449B/ | PTO | Complete if Known | | |
|-------|------------------|-------------|----------|------------------------|---------------------------|--|
| | INFORMATIO | N DISCLO | SURE | Application Number | 10/522,130 | |
| | STATEMENT | BY APPLI | CANT | Filing Date | 01/19/2005 | |
| | | | | First Named Inventor | Murray Goodman | |
| | | | | Group Art Unit | | |
| | (use as many sh | eets as ne | cessary) | Examiner Name | | |
| Sheet | 2 | of | 2 | Attorney Docket Number | SDUC1100J-1 (041673-3109) | |

| | | NON PATENT LITERATURE DOCUMENTS | | | | |
|-----------------------|-----|---|--|--|--|--|
| Examiner Initials* | | | | | | |
| | A10 | PEPINSKY, R.B. et al., Specific Inhibition of a Human Papillomavirus E2 <i>Trans</i> -Activator by Intracellular Delivery of Its Repressor, DNA Cell Biol., 13, p. 1011-1019 (1994). | | | | |
| | A11 | RYSER, H.JP., A Membrane Effect of Basic Polymers dependent on Molecular Size, Nature (London), 215, p. 934-936 (1967). | | | | |
| | A12 | overcomes drug resistance in cultured cells, Proc. Nat. Acad. Sci. USA., 75, p. 3867-3870 (1978). | | | | |
| | A13 | SCHWARZE, S.R. et al., In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse, Science, 285, p. 1569-1572 (1999). | | | | |
| | A14 | SHEN, W., et al., Conjugation of poly-L-lysine to albumin and horseradish peroxides: A novel method of enhancing the cellular uptake of proteins, Proc. Nat. Acad. Sci. USA., 75, p. 1872-1876 (1978). | | | | |
| | A15 | VOCERO-AKBANI, A.M. et al., Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein, Nat. Med., 5, p. 29-33 (1999). | | | | |
| | A16 | WENDER, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters, Proc. Natl. Acad. Sci. USA., 97, p. 13003-13008 (2000). | | | | |

| | | | · · · · · · · · · · · · · · · · · · · |
|-----------|---------------------------------------|------------|---------------------------------------|
| E | · · · · · · · · · · · · · · · · · · · | Date | |
| Examiner | | Considered | |
| Signature | | Considered | <u> </u> |
| | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, thickde copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emiperor must precede the serial number of the patent document. *Fixind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DLMR_280342.1